Effect of therapeutic drug monitoring-based dose optimization of piperacillin/tazobactam on sepsis-related organ dysfunction in patients with sepsis: a randomized controlled trial

Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021

(2021) Laura Evans et al.   INTENSIVE CARE MEDICINE

Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper#

(2020) Mohd H. Abdul-Aziz et al.   INTENSIVE CARE MEDICINE

Time above the MIC of Piperacillin-Tazobactam as a Predictor of Outcome in Pseudomonas aeruginosa Bacteremia

(2020) Elias Tannous et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Therapeutic Monitoring of Vancomycin for Serious Methicillin-resistant Staphylococcus aureus Infections: A Revised Consensus Guideline and Review by the American Society of Health-system Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists

(2020) Michael J Rybak et al.   CLINICAL INFECTIOUS DISEASES

Therapeutic drug monitoring-based dose optimisation of piperacillin/tazobactam to improve outcome in patients with sepsis (TARGET): a prospective, multi-centre, randomised controlled trial

(2019) Stefan Hagel et al.   Trials

Therapeutic drug monitoring-guided continuous infusion of piperacillin/tazobactam significantly improves pharmacokinetic target attainment in critically ill patients: a retrospective analysis of four years of clinical experience

(2019) Daniel C. Richter et al.   INFECTION

Early target attainment of continuous infusion piperacillin/tazobactam and meropenem in critically ill patients: A prospective observational study

(2019) Sofie A.M. Dhaese et al.   JOURNAL OF CRITICAL CARE

Comparison of piperacillin exposure in the lungs of critically ill patients and healthy volunteers

(2018) T W Felton et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Higher than standard dosing regimen are needed to achieve optimal antibiotic exposure in critically ill patients with augmented renal clearance receiving piperacillin-tazobactam administered by continuous infusion

(2018) Cédric Carrié et al.   JOURNAL OF CRITICAL CARE

MIC-based dose adjustment: facts and fables

(2017) Johan W Mouton et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Continuous versus Intermittent β-Lactam Infusion in Severe Sepsis. A Meta-analysis of Individual Patient Data from Randomized Trials

(2016) Jason A. Roberts et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)

(2016) Mervyn Singer et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Can therapeutic drug monitoring optimize exposure to piperacillin in febrile neutropenic patients with haematological malignancies? A randomized controlled trial

(2015) Fekade Bruck Sime et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Therapeutic drug monitoring of the β-lactam antibiotics: what is the evidence and which patients should we be using it for?: Figure 1.

(2015) Angela Huttner et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

DALI: Defining Antibiotic Levels in Intensive Care Unit Patients: Are Current  -Lactam Antibiotic Doses Sufficient for Critically Ill Patients?

(2014) J. A. Roberts et al.   CLINICAL INFECTIOUS DISEASES

Therapeutic drug monitoring-based dose optimisation of piperacillin and meropenem: a randomised controlled trial

(2013) Jan J. De Waele et al.   INTENSIVE CARE MEDICINE

Effect of Empirical Treatment With Moxifloxacin and Meropenem vs Meropenem on Sepsis-Related Organ Dysfunction in Patients With Severe Sepsis

(2012) Frank M. Brunkhorst   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Therapeutic drug monitoring of β-lactams in critically ill patients: proof of concept

(2010) Jason A. Roberts et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS